PIPE-505 + Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sensorineural Hearing Loss
Conditions
Sensorineural Hearing Loss
Trial Timeline
Oct 15, 2020 → Jun 17, 2021
NCT ID
NCT04462198About PIPE-505 + Placebo
PIPE-505 + Placebo is a phase 1/2 stage product being developed by Contineum Therapeutics for Sensorineural Hearing Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT04462198. Target conditions include Sensorineural Hearing Loss.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04462198 | Phase 1/2 | Completed |
Competing Products
2 competing products in Sensorineural Hearing Loss
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| PF-04958242 + PF-04958242 + Placebo | Biogen | Phase 1 | 30 |
| SENS-401 + SENS-401 | Sensorion | Phase 2/3 | 57 |